Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes

Journal of Cardiovascular Pharmacology

Volumn 40, Issue 4, 2002, Pages 611-617

  Delbosc, Sandrine ^a   Morena, Marion ^a   Djouad, Farida ^a   Ledoucen, Christian ^a   Descomps, Bernard ^a   Cristol, Jean Paul ^a  

^a Lab de Nutr Humaine/Atherogenese   (France)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; NADPH oxidase; Reactive oxygen species

Indexed keywords

CELL PROTEIN; CERIVASTATIN; FLUINDOSTATIN; GERANYLGERANIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; PROTEIN FARNESYLTRANSFERASE; PROTEIN P21; PROTEIN P67; RAC PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIMVASTATIN; STATIN; SUPEROXIDE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL LINE; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME MODIFICATION; HUMAN; MONOCYTE; OXIDATIVE STRESS; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN TRANSPORT;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MONOCYTES; NADPH OXIDASE; SUPEROXIDES; TUMOR CELLS, CULTURED;

EID: 0036785795     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200210000-00015     Document Type: Article

References (34)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Steinberg D, Parthasarathy S, Carew T. Beyond cholesterol: modification of low density lipoproteins that increase its atherogenicity. N Engl J Med 1989;320:915-29.
3. Hidaka Y, Eda T, Yonemoto M, et al. Inhibition of cultured vascular smooth muscle cell migration by simvastatin. Atherosclerosis 1992;95:87-94.
4. Lum H, Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physiol 2001;280: C719-41.
5. Channock S, Benna J, Smith R, et al. The respiratory burst oxidase. J Biol Chem 1994;269:40:24519-22.
6. Babior BM. NADPH oxidase: an update. Blood 1999;93:1464-76.
7. Freeman J, Abo A, Lambeth J. Rac "insert region" is a novel effector region that is implicated in the NADPH activation of NADPH oxidase, but not PAK 65. J Biol Chem 1996;271:19794-801.
8. Ando S, Baibuchi K, Sasaki T, et al. Post-translational processing of rac p21s is important for their interaction with the GDP/GTP exchange proteins and for their activation of NADPH oxidase. J Biol Chem 1992;267:25709-13.
9. Benna E, Han J, Park J, et al. Activation of p38 in stimulated human neutrophils: phosphorylation of the oxydase component p47phox by p38 and ERK but not JNK. Arch Biochem Biophys 1996;334:395-400.
10. Levine G, Keaney J, Vita J. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995;332:512-21.
11. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993;1165:335-8.
12. Colli S, Eligini S, Lulli M, et al. Vastatins inhibit tissue factor in cultured human macrophages. Arterioscler Thromb Vasc Biol 1997;17:265-71.
13. Keyomarsi K, Sandoval L, Band V, et al. Synchronisation of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991;51:3602-9.
14. Vachier I, Chanez P, Doucen CL, et al. Enhancement of reactive oxygen species formation in stable and unstable asthmatic patients. Eur Respir J 1994;7:1585-92.
15. Lowry O, Rosebrough N, Farr A, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
16. Dusi S, Donini M, Rossi F. Mechanisms of NADPH oxidase activation in human neutrophils: p67 phox is required for the translocation of rac1 but not rac 2 from the cytosol to the membranes. Biochem J 1995;308:991-4.
17. Bokoch GM, Prossnitz V. Isoprenoid metabolism is required for stimulation of the respiratory burst oxidase of HL-60 cells. J Clin Invest 1992;89:402-8.
18. Wagner AH, Kohler T, Ruckschloss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61-9.
19. Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001;59:646-54.
20. Nisimoto Y, Motalebi S, Han CH, et al. The p67(phox) activation domain regulates electron flow from NADPH to flavin in flavocytochrome b(558). J Biol Chem 1999;274:22999-3005.
21. Kreck ML, Freeman JL, Abo A, et al. Membrane association of Rac is required for high activity of the respiratory burst oxidase. Biochemistry 1996;35:15683-92.
22. Bellosta S, Bernini F, Ferri N, et al. Direct vascular effect of HMG CoA reductase inhibitors. Atherosclerosis 1998;137(suppl):S101-9.
23. Shepherd J. Preventing coronary artery disease in the West of Scotland: implications for primary prevention. Am J Cardiol 1998;82:57T-59T.
24. The Long Term Investigators with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin on patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
25. Sacks FM, Ridker PM. Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events. Herz 1999;24:51-6.
26. Albert MA, Staggers J, Chew P, et al. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Am Heart J 2001;141:893-8.
27. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-44.
28. Kanno T, Utsumi T, Takehara Y, et al. Inhibition of neutrophil-superoxide generation by alpha-tocopherol and coenzyme Q. Free Radic Res 1996;24:281-9.
29. Cachia O, Benna JE, Pedruzzi E, et al. Alpha-tocopherol inhibits the respiratory burst in human monocytes: attenuation of p47(phox) membrane translocation and phosphorylation. J Biol Chem 1998;273:32801-5.
30. Anderson TJ, Meredith IT, Charbonneau F, et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996;93:1647-50.
31. Singh RB, Singh NK, Rastogi SS, et al. Antioxidant effects of lovastatin and vitamin E on experimental atherosclerosis in rabbits. Cardiovasc Drugs Ther 1997;11:575-80.
32. Tomas M, Senti M, Garcia-Faria F, et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2000;20:2113-9.
33. Sano M, Fukuda K, Sato T, et al. ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts. Circ Res 2001;89:661-9.
34. Schieffer B, Luchtefeld M, Braun S, et al. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res 2000;87:1195-201.